Comparison of the effects of three kinds of glucose‐lowering drugs on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open‐label, three‐arm, active control study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparison of the effects of three kinds of glucose‐lowering drugs on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open‐label, three‐arm, active control study
Authors
Keywords
-
Journal
Journal of Diabetes Investigation
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-04-24
DOI
10.1111/jdi.13279
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
- (2019) Lee-Lee Lai et al. DIGESTIVE DISEASES AND SCIENCES
- Adiponectin and PPAR: a setup for intricate crosstalk between obesity and non-alcoholic fatty liver disease
- (2019) Syeda Momna Ishtiaq et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Effects of liraglutide, metformin, and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial
- (2018) Wen-Huan Feng et al. Journal of Diabetes Investigation
- Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease
- (2018) Masanori Shimizu et al. DIABETES OBESITY & METABOLISM
- Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease
- (2018) Mitsuko Inoue et al. Journal of Diabetes Investigation
- Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
- (2018) Yuya Seko et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus
- (2017) Yoshio Sumida et al. HEPATOLOGY RESEARCH
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nonalcoholic fatty liver disease: Evolving paradigms
- (2017) Amedeo Lonardo et al. WORLD JOURNAL OF GASTROENTEROLOGY
- The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans
- (2016) Stefano Ballestri et al. ADVANCES IN THERAPY
- Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions
- (2016) Kenneth Cusi DIABETOLOGIA
- Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis
- (2016) Stefano Ballestri et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
- (2016) Yasushi Honda et al. PLoS One
- Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats
- (2015) Yuka Hayashizaki-Someya et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Nonalcoholic Fatty Liver Disease
- (2015) Mary E. Rinella JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis
- (2015) Lana Pinto et al. Diabetology & Metabolic Syndrome
- Effects of Pioglitazone on Visceral Fat Metabolic Activity in Impaired Glucose Tolerance or Type 2 Diabetes Mellitus
- (2013) Norihiro Kodama et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population
- (2012) Yoshio Sumida et al. BMC GASTROENTEROLOGY
- Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
- (2012) G. Musso et al. DIABETOLOGIA
- Thiazolidinediones and PPARγ agonists: time for a reassessment
- (2012) Bertrand Cariou et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- The role of thiazolidinediones in non-alcoholic steatohepatitis – A systematic review and meta analysis
- (2011) Suzanne E. Mahady et al. JOURNAL OF HEPATOLOGY
- A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease
- (2010) Yoshio Sumida et al. JOURNAL OF GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started